Literature DB >> 3930389

Pathogenesis of Yersinia-triggered reactive arthritis: immunological, microbiological and clinical aspects.

A Toivanen, K Granfors, R Lahesmaa-Rantala, R Leino, T Ståhlberg, R Vuento.   

Abstract

When a patient develops reactive arthritis after Yersinia enteritis, the following conditions are often fulfilled: the patient is HLA-B27-positive; however, some B27-negative individuals develop severe arthritis and some positives do not, in the initial phase, the diarrhea is milder, the anti-Yersinia antibody response of IgG class is more vigorous and persists longer, the anti-Yersinia antibody response of IgA class is more vigorous and persists much longer, the anti-Yersinia antibodies of IgA1 and IgA2 subclass, those with J-chain and, especially, those with secretory piece are produced more vigorously, indicating local immunostimulation close to the intestinal epithelium, in the early phase, Yersinia-IgM immune complexes are found in the circulation, and the lymphocyte transformation response against not only Yersinia but also against other gram-negative enteric bacteria is weaker. When all these aspects are considered together a strong suspicion arises that the patients who are destined to develop reactive arthritis fail in their first line of defense against the invading organism when contracting a Yersinia enteritis. This may lead to persistence of the microorganism within the body, e.g., in the intestinal epithelium or in the mesenteric lymphoid tissues, maintaining a stimulus for a prolonged--apparently futile and perhaps harmful--antibody production. Finally, the initiating and decisive factor should not be forgotten: the Yersinia. Why and how it triggers the process is at present one of the enigmas of the pathogenesis of reactive arthritis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930389     DOI: 10.1111/j.1600-065x.1985.tb01137.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  43 in total

Review 1.  Bacteria-Triggered reactive arthritis: implications for antibacterial treatment.

Authors:  A Toivanen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Clinically silent infections in patients with oligoarthritis: results of a prospective study.

Authors:  C M Weyand; J J Goronzy
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

3.  Plasmid-encoded outer membrane protein YadA mediates specific binding of enteropathogenic yersiniae to various types of collagen.

Authors:  H Schulze-Koops; H Burkhardt; J Heesemann; K von der Mark; F Emmrich
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Antibodies to the peptide from the plasmid-coded Yersinia outer membrane protein (YOP1) in patients with ankylosing spondylitis.

Authors:  N Tsuchiya; G Husby; R C Williams
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

5.  Determination of oxygen radical production in spondyloarthropathies by whole blood chemiluminescence.

Authors:  M Ristola; M Leirisalo-Repo; H Repo
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

6.  Invasin of Yersinia pseudotuberculosis activates human peripheral B cells.

Authors:  E Lundgren; N Carballeira; R Vazquez; E Dubinina; H Bränden; H Persson; H Wolf-Watz
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

7.  Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous Yersinia arthritis.

Authors:  H Repo; M Jäättelä; M Leirisalo-Repo; M Hurme
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

8.  T lymphocytes mediate protection against Yersinia enterocolitica in mice: characterization of murine T-cell clones specific for Y. enterocolitica.

Authors:  I B Autenrieth; A Tingle; A Reske-Kunz; J Heesemann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

9.  Yersinia pseudotuberculosis and arthritis.

Authors:  G E Bignardi
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

10.  Ankylosing spondylitis and HLA-B27: restriction fragment length polymorphism and sequencing of an HLA-B27 allele from a patient with ankylosing spondylitis.

Authors:  C M Higgins; T Lund; M E Shipley; A Ebringer; M Sadowska-Wroblewska; R K Craig
Journal:  Ann Rheum Dis       Date:  1992-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.